Skip to main content

Advertisement

Table 1 Examples of clinical trials using VOA

From: Innovations in the quantitative virus outgrowth assay and its use in clinical trials

Clinical trial no. Intervention Key finding References
NCT01319383 Vorinostat (single dose) 8 patients Single dose of vorinostat increased cell-associated RNA in resting CD4 cells but no reduction in IUPM [26]
NCT01319383 Vorinostat (multiple doses 3 ×/week for 8 weeks) 5 patients Increase in cell-associated RNA with multiple doses compared to single dose of vorinostat in 3/5 patients, no reduction in IUPM [27]
NCT01319383 Vorinostat (multiple doses) 16 patients Multiple doses of vorinostat increased cell-associated RNA in resting CD4 cells but no reduction in IUPM [28]
NCT01680094 Panobinostat 15 patients Increase in cell-associated RNA, increase in plasma viraemia, no significant reduction in total and integrated DNA or IUPM. No delay in time to rebound in the 9 patients undergoing planned treatment interruption. [29]
NCT00289952 Valproic acid and ART 56 patients No reduction in IUPM [30]
NCT01286259 Disulfiram 16 patients Transient increase in plasma viraemia in a subset of patients, no overall change in plasma viraemia in the entire cohort, no change in IUPM [31]
NCT02443935 MGN1703 15 patients Significant reduction in cell-associated RNA post-treatment, transient increase in plasma viraemia in 6/15 patients. No change in total or integrated HIV DNA, also no change in IUPM [32]
NCT02092116
REDUC
Romidepsin, Vacc-4x and rhuGM-CSF 20 patients (17 completed trial) Significant decrease (40%) in total DNA (in 16 patients measurable), non-significant decrease (19%) in integrated DNA (15 patients measurable) significant reduction (38%) in IUPM (6 patients measurable). No delay in time to rebound in the 15 patients who have undergone post treatment interruption [19]
NCT02336074 RIVER ART, Raltegravir, Vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv Ongoing  
NCT02707900 VORVAX Vorinostat and AGS-004 Ongoing  
NCT02471430
ACTIVATE
Panobinostat and Pegylated Interferon-alpha2a Ongoing  
NCT02408861 Nivolumab and Ipilimumab Ongoing  
  1. IUPM infectious units per million cells as measured by VOA